What is the 13F Pro Quality Score for CYCN?

13F Pro ranks Cyclerion Therapeutics, Inc. (CYCN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CYCN's current score at https://13fpro.ai/research/CYCN (free sign-up required for the full ranking).

Which hedge funds own the most CYCN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CYCN include GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CYCN as soon as new 13F filings post.

Where does 13F Pro source CYCN data?

All Cyclerion Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cyclerion Therapeutics, Inc. files with the SEC under CIK 1755237. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CYCN in?

Cyclerion Therapeutics, Inc. (CYCN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CYCN research updated on 13F Pro?

CYCN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cyclerion Therapeutics, Inc.(CYCN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1755237 CYCN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CYCN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cyclerion Therapeutics, Inc. (CYCN), a Healthcare sector company. CYCN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Cyclerion Therapeutics, Inc. reports net income of $-3.2M, free cash flow of $-1.2M. Top institutional holders of CYCN by reported 13-F value include GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, BlackRock,, based on the most recent SEC filings. CYCN trades on the Nasdaq exchange and files with the SEC under CIK 1755237. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cyclerion Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-3.2M

Free Cash Flow

Q1 2026

$-1.2M

ROIC

Q1 2026

-47.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-92.5% YoY

$297.0KFY 2022

FY18 —FY20 $2.3MFY21 $3.9MFY22 $297.0K

Net Income

+185.4% YoY

$44.1MFY 2022

FY18 $-115.3MFY20 $-77.8MFY21 $-51.6MFY22 $44.1M

Operating Income

+66.4% YoY

$-18.5MFY 2022

FY18 $-115.3MFY20 $-81.3MFY21 $-55.2MFY22 $-18.5M

EPS (Diluted)

-1436.4% YoY

$-20.28FY 2022

FY18 —FY20 —FY21 $-1.32FY22 $-20.28

Total Assets

-69.5% YoY

$18.1MFY 2022

FY18 $7.4MFY20 $115.4MFY21 $59.3MFY22 $18.1M

Total Debt

+0.0% YoY

$3.5MFY 2022

FY18 —FY20 $3.5MFY21 $3.5MFY22 $3.5M

Op. Cash Flow

-11.2% YoY

$-40.6MFY 2022

FY18 $-97.5MFY20 $-72.5MFY21 $-36.5MFY22 $-40.6M

Metric	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$297.0K -92.5%	$3.9M +71.7%	$2.3M	—	—
Net Income	$44.1M +185.4%	$-51.6M +33.6%	$-77.8M +32.5%	$-115.3M	—
Operating Income	$-18.5M +66.4%	$-55.2M +32.1%	$-81.3M +29.5%	$-115.3M	—
EPS (Diluted)	$-20.28 -1436.4%	$-1.32	—	—	—
Total Assets	$18.1M -69.5%	$59.3M -48.6%	$115.4M +1459.0%	$7.4M	—
Total Debt	$3.5M +0.0%	$3.5M +0.0%	$3.5M	—	—
Operating Cash Flow	$-40.6M -11.2%	$-36.5M +49.6%	$-72.5M +25.7%	$-97.5M	—

AI Insight: CYCN Financial Trends

Cyclerion remains pre-revenue with widening losses; Q1 2026 operating income deteriorated to −$3M while equity eroded to $7M.

• Revenue minimal and inconsistent: $2M in Q4 2024, then $0–$1M thereafter through Q1 2026.

• Operating losses accelerating: Q1 2026 operating income of −$3M worst in the trailing 9 quarters.

• Shareholder equity declined from $10M in Q3 2025 to $7M in Q1 2026 amid cumulative net losses.

⚠ Cash burn persists: operating cash flow negative in 6 of last 8 quarters; Q4 2025 and Q1 2026 each −$1M to −$2M.

⚠ Equity runway limited at current burn rate; balance sheet deterioration may force capital raise or strategic action.

AI Insight: CYCN Ratio Trends

Cyclerion has collapsed to severe operating losses and deeply negative returns across all efficiency metrics, with no sign of stabilization through Q1 2026.

• Operating margin deteriorated from +27.8% in Q4 2024 to -81.8% in Q4 2025, then worsened further in Q1 2026 TTM at -99.0%.

• ROIC swung from +22.7% in Q4 2024 to -36.9% in Q4 2025 and -99.0% TTM; sustained negative capital returns over nine months.

• ROE fell from +23.9% in Q4 2024 to -187.1% in Q1 2026 TTM, reflecting accelerating shareholder value destruction.

⚠ Q4 2024 was an isolated profitable quarter; losses have persisted and worsened for five consecutive quarters since Q1 2025.

⚠ Q1 2026 TTM ROE of -187.1% suggests compounding losses; underlying business trajectory demands urgent strategic intervention.

Get alerted when CYCN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cyclerion Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CYCN

GEODE CAPITAL MANAGEMENT, LLC
$129.8K84,550 sh
CITADEL ADVISORS LLC
$28.0K18,261 sh
BlackRock, Inc.
$26.0K16,797 sh
VANGUARD CAPITAL MANAGEMENT LLC
$24.8K16,137 sh
Kovack Advisors, Inc.
$15.5K10,000 sh
VANGUARD FIDUCIARY TRUST CO
$11.3K7,353 sh
FMR LLC
$7.3K4,740 sh
UBS Group AG
$5.3K3,391 sh
GROUP ONE TRADING, L.P.
$295.00192 sh
OSAIC HOLDINGS, INC.
$201.00130 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$129.8K	84,550
CITADEL ADVISORS LLC	$28.0K	18,261
BlackRock, Inc.	$26.0K	16,797
VANGUARD CAPITAL MANAGEMENT LLC	$24.8K	16,137
Kovack Advisors, Inc.	$15.5K	10,000
VANGUARD FIDUCIARY TRUST CO	$11.3K	7,353
FMR LLC	$7.3K	4,740
UBS Group AG	$5.3K	3,391
GROUP ONE TRADING, L.P.	$295.00	192
OSAIC HOLDINGS, INC.	$201.00	130

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CYCN on your watchlist

Track score changes the day Cyclerion Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CYCN a good stock to buy?

13F Pro's AI-powered analysis of Cyclerion Therapeutics, Inc. (CYCN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYCN are available on the CYCN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CYCN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYCN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cyclerion Therapeutics, Inc.'s investment landscape.